Cargando…

初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究

OBJECTIVE: To analyze the frequency and composition of risk-related cytogenetic abnormalities (CAs) in patients with newly-diagnosed multiple myeloma (NDMM). METHODS: The frequency and composition of risk-related CAs from a cohort of 1 015 Chinese patients with NDMM were determined by interphase flu...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial office of Chinese Journal of Hematology 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357912/
https://www.ncbi.nlm.nih.gov/pubmed/32023748
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.01.003
_version_ 1783558753441808384
collection PubMed
description OBJECTIVE: To analyze the frequency and composition of risk-related cytogenetic abnormalities (CAs) in patients with newly-diagnosed multiple myeloma (NDMM). METHODS: The frequency and composition of risk-related CAs from a cohort of 1 015 Chinese patients with NDMM were determined by interphase fluorescence in situ hybridization (iFISH), individually or in combination. RESULTS: Of the cohort of 1 015 Chinese patients with NDMM, the frequencies of IgH arrangement, del (13q) /13q14, 1q gain and del (17p) were 54.0%, 46.4%, 46.1% (35.8% and 12. 7% for 3 or more than 3 copies) and 9.9%, respectively. Among 454 patients who had the baseline information for all risk-related CAs [except t (14;20), which was not covered by the FISH panels performed routinely at all five centers], the frequencies of t (4;14), t (11;14) or t (14;20) were 14.1%, 11.2% and 4.8%, respectively; of them, 44.3% patients carried 2 or more CAs (28.0%, 13.4% and 2.9% for 2, 3 or ≥4 CAs); 83.3%, 95.0% or 68.6% patients with 1q gain, del (17p) or IgH rearrangement had 1 or more additional CA (s), with del (13q) /13q14 as the most frequently accompanied CA; 57.7% patients carried at least 1 HRCA; the incidences of double-hit (DH) MM (DHMM) (=2 HRCAs) and triple-hit (TH) (THMM) (≥3 HRCAs) were 14.3% and 2.9%, respectively. CONCLUSIONS: Our results provided an up-to-date profile of CAs in Chinese NDMM patients, which revealed that approximately 58% patients might carry at least 1 HRCA, and 17% could experience so-called DHMM or THMM who presumably had the worst outcome.
format Online
Article
Text
id pubmed-7357912
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Editorial office of Chinese Journal of Hematology
record_format MEDLINE/PubMed
spelling pubmed-73579122020-07-16 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究 Zhonghua Xue Ye Xue Za Zhi 论著 OBJECTIVE: To analyze the frequency and composition of risk-related cytogenetic abnormalities (CAs) in patients with newly-diagnosed multiple myeloma (NDMM). METHODS: The frequency and composition of risk-related CAs from a cohort of 1 015 Chinese patients with NDMM were determined by interphase fluorescence in situ hybridization (iFISH), individually or in combination. RESULTS: Of the cohort of 1 015 Chinese patients with NDMM, the frequencies of IgH arrangement, del (13q) /13q14, 1q gain and del (17p) were 54.0%, 46.4%, 46.1% (35.8% and 12. 7% for 3 or more than 3 copies) and 9.9%, respectively. Among 454 patients who had the baseline information for all risk-related CAs [except t (14;20), which was not covered by the FISH panels performed routinely at all five centers], the frequencies of t (4;14), t (11;14) or t (14;20) were 14.1%, 11.2% and 4.8%, respectively; of them, 44.3% patients carried 2 or more CAs (28.0%, 13.4% and 2.9% for 2, 3 or ≥4 CAs); 83.3%, 95.0% or 68.6% patients with 1q gain, del (17p) or IgH rearrangement had 1 or more additional CA (s), with del (13q) /13q14 as the most frequently accompanied CA; 57.7% patients carried at least 1 HRCA; the incidences of double-hit (DH) MM (DHMM) (=2 HRCAs) and triple-hit (TH) (THMM) (≥3 HRCAs) were 14.3% and 2.9%, respectively. CONCLUSIONS: Our results provided an up-to-date profile of CAs in Chinese NDMM patients, which revealed that approximately 58% patients might carry at least 1 HRCA, and 17% could experience so-called DHMM or THMM who presumably had the worst outcome. Editorial office of Chinese Journal of Hematology 2020-01 /pmc/articles/PMC7357912/ /pubmed/32023748 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.01.003 Text en 2020年版权归中华医学会所有 http://creativecommons.org/licenses/by-nc-sa/3.0/ This work is licensed under a Creative Commons Attribution 3.0 License (CC-BY-NC). The Copyright own by Publisher. Without authorization, shall not reprint, except this publication article, shall not use this publication format design. Unless otherwise stated, all articles published in this journal do not represent the views of the Chinese Medical Association or the editorial board of this journal.
spellingShingle 论著
初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
title 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
title_full 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
title_fullStr 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
title_full_unstemmed 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
title_short 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
title_sort 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究
topic 论著
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7357912/
https://www.ncbi.nlm.nih.gov/pubmed/32023748
http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2020.01.003
work_keys_str_mv AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū
AT chūzhìduōfāxìnggǔsuǐliúhuànzhěxìbāoyíchuánxuéyìchángliúxíngbìngxuédeduōzhōngxīnhuígùxìngyánjiū